(CON) Concentra Holdings Parent - Overview
Stock: Occupational Health, Telemedicine, Pharmacy, Compliance Testing, Injury Care
Dividends
| Dividend Yield | 1.16% |
| Yield on Cost 5y | 1.14% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 100.0% |
| Payout Ratio | 24.2% |
| Risk 5d forecast | |
|---|---|
| Volatility | 29.6% |
| Relative Tail Risk | -6.59% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.08 |
| Alpha | -10.06 |
| Character TTM | |
|---|---|
| Beta | 0.689 |
| Beta Downside | 0.789 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.58% |
| CAGR/Max DD | 0.17 |
Description: CON Concentra Holdings Parent January 12, 2026
Concentra Group Holdings Parent, Inc. (NYSE: CON) delivers a full suite of occupational health services across the United States, ranging from workers-compensation care and employer-sponsored primary care to mobile health, telemedicine (Concentra Telemed), pharmacy repackaging, and third-party compliance administration for drug-testing programs.
Founded in 1979 and headquartered in Addison, Texas, Concentra operates clinics, urgent-care centers, and on-site health units that provide injury care, preventive services, clinical testing, vaccinations, and consultative risk-management for both regulated and non-regulated workforces.
Key performance indicators (KPIs) from the most recent fiscal year show revenue of roughly $1.5 billion, an adjusted EBITDA margin near 12 %, and a 30 % year-over-year increase in telemedicine visit volume-reflecting broader employer adoption of virtual care solutions.
Sector drivers include rising employer spending on employee health benefits (U.S. employer health-care costs grew 5.2 % YoY in 2023), a tightening labor market that heightens the value of on-site health services, and ongoing consolidation in the occupational-health space, which could create acquisition opportunities for larger health-system players.
For a deeper quantitative dive, the ValueRay platform offers a granular, data-driven view of CON’s valuation metrics.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 167.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.71 > 1.0 |
| NWC/Revenue: 3.87% < 20% (prev 6.84%; Δ -2.98% < -1%) |
| CFO/TA 0.09 > 3% & CFO 254.4m > Net Income 167.9m |
| Net Debt (2.14b) to EBITDA (355.1m): 6.03 < 3 |
| Current Ratio: 1.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (128.2m) vs 12m ago 0.04% < -2% |
| Gross Margin: 29.08% > 18% (prev 0.29%; Δ 2879 % > 0.5%) |
| Asset Turnover: 58.61% > 50% (prev 70.41%; Δ -11.80% > 0%) |
| Interest Coverage Ratio: 3.39 > 6 (EBITDA TTM 355.1m / Interest Expense TTM 77.8m) |
Altman Z'' 0.92
| A: 0.02 (Total Current Assets 375.4m - Total Current Liabilities 312.6m) / Total Assets 2.84b |
| B: 0.04 (Retained Earnings 120.1m / Total Assets 2.84b) |
| C: 0.10 (EBIT TTM 263.5m / Avg Total Assets 2.77b) |
| D: 0.0 (Book Value of Equity 0.0 / Total Liabilities 2.43b) |
| Altman-Z'' Score: 0.92 = BB |
What is the price of CON shares?
Over the past week, the price has changed by +6.09%, over one month by +18.03%, over three months by +22.39% and over the past year by +4.64%.
Is CON a buy, sell or hold?
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CON price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.4 | 21% |
| Analysts Target Price | 28.4 | 21% |
| ValueRay Target Price | 25.7 | 9.4% |
CON Fundamental Data Overview February 03, 2026
P/E Forward = 14.3062
P/S = 1.3606
P/B = 7.1817
Revenue TTM = 1.62b USD
EBIT TTM = 263.5m USD
EBITDA TTM = 355.1m USD
Long Term Debt = 1.60b USD (from longTermDebt, two quarters ago)
Short Term Debt = 95.7m USD (from shortTermDebt, two quarters ago)
Debt = 2.14b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = 2.14b USD (using Total Debt 2.14b, CCE unavailable)
Enterprise Value = 4.98b USD (2.84b + Debt 2.14b - (null CCE))
Interest Coverage Ratio = 3.39 (Ebit TTM 263.5m / Interest Expense TTM 77.8m)
EV/FCF = 28.39x (Enterprise Value 4.98b / FCF TTM 175.6m)
FCF Yield = 3.52% (FCF TTM 175.6m / Enterprise Value 4.98b)
FCF Margin = 10.81% (FCF TTM 175.6m / Revenue TTM 1.62b)
Net Margin = 10.33% (Net Income TTM 167.9m / Revenue TTM 1.62b)
Gross Margin = 29.08% ((Revenue TTM 1.62b - Cost of Revenue TTM 1.15b) / Revenue TTM)
Gross Margin QoQ = none% (prev 29.20%)
Tobins Q-Ratio = 1.75 (Enterprise Value 4.98b / Total Assets 2.84b)
Interest Expense / Debt = 1.34% (Interest Expense 28.7m / Debt 2.14b)
Taxrate = 21.0% (US default 21%)
NOPAT = 208.1m (EBIT 263.5m * (1 - 21.00%))
Current Ratio = 1.20 (Total Current Assets 375.4m / Total Current Liabilities 312.6m)
Debt / Equity = 5.55 (Debt 2.14b / totalStockholderEquity, two quarters ago 385.5m)
Debt / EBITDA = 6.03 (Net Debt 2.14b / EBITDA 355.1m)
Debt / FCF = 12.19 (Net Debt 2.14b / FCF TTM 175.6m)
Total Stockholder Equity = 327.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.06% (Net Income 167.9m / Total Assets 2.84b)
RoE = 51.22% (Net Income TTM 167.9m / Total Stockholder Equity 327.7m)
RoCE = 13.66% (EBIT 263.5m / Capital Employed (Equity 327.7m + L.T.Debt 1.60b))
RoIC = 10.50% (NOPAT 208.1m / Invested Capital 1.98b)
WACC = 5.27% (E(2.84b)/V(4.98b) * Re(8.45%) + D(2.14b)/V(4.98b) * Rd(1.34%) * (1-Tc(0.21)))
Discount Rate = 8.45% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.62%
[DCF Debug] Terminal Value 86.36% ; FCFF base≈179.7m ; Y1≈180.0m ; Y5≈191.4m
Fair Price DCF = 27.82 (EV 5.71b - Net Debt 2.14b = Equity 3.57b / Shares 128.2m; r=5.90% [WACC]; 5y FCF grow -0.34% → 2.90% )
EPS Correlation: -59.82 | EPS CAGR: -83.76% | SUE: 0.0 | # QB: 0
Revenue Correlation: 80.32 | Revenue CAGR: 9.52% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.36 | Chg30d=-0.006 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=1.48 | Chg30d=-0.016 | Revisions Net=-2 | Growth EPS=+13.1% | Growth Revenue=+7.5%